RESUMEN
We studied the localization of 6-phosphogluconate dehydrogenase (PGD) isoforms of Arabidopsis (Arabidopsis thaliana). Similar polypeptide lengths of PGD1, PGD2, and PGD3 obscured which isoform may represent the cytosolic and/or plastidic enzyme plus whether PGD2 with a peroxisomal targeting motif also might target plastids. Reporter-fusion analyses in protoplasts revealed that, with a free N terminus, PGD1 and PGD3 accumulate in the cytosol and chloroplasts, whereas PGD2 remains in the cytosol. Mutagenesis of a conserved second ATG enhanced the plastidic localization of PGD1 and PGD3 but not PGD2. Amino-terminal deletions of PGD2 fusions with a free C terminus resulted in peroxisomal import after dimerization, and PGD2 could be immunodetected in purified peroxisomes. Repeated selfing of pgd2 transfer (T-)DNA alleles yielded no homozygous mutants, although siliques and seeds of heterozygous plants developed normally. Detailed analyses of the C-terminally truncated PGD2-1 protein showed that peroxisomal import and catalytic activity are abolished. Reciprocal backcrosses of pgd2-1 suggested that missing PGD activity in peroxisomes primarily affects the male gametophyte. Tetrad analyses in the quartet1-2 background revealed that pgd2-1 pollen is vital and in vitro germination normal, but pollen tube growth inside stylar tissues appeared less directed. Mutual gametophytic sterility was overcome by complementation with a genomic construct but not with a version lacking the first ATG. These analyses showed that peroxisomal PGD2 activity is required for guided growth of the male gametophytes and pollen tube-ovule interaction. Our report finally demonstrates an essential role of oxidative pentose-phosphate pathway reactions in peroxisomes, likely needed to sustain critical levels of nitric oxide and/or jasmonic acid, whose biosynthesis both depend on NADPH provision.
Asunto(s)
Proteínas de Arabidopsis/antagonistas & inhibidores , Arabidopsis/metabolismo , Células Germinativas de las Plantas/efectos de los fármacos , Fosfogluconato Deshidrogenasa/antagonistas & inhibidores , Prostaglandina D2/antagonistas & inhibidores , Isoformas de Proteínas/antagonistas & inhibidores , Alelos , Arabidopsis/enzimología , Arabidopsis/genética , Arabidopsis/crecimiento & desarrollo , Proteínas de Arabidopsis/genética , Clonación Molecular , Ciclopentanos/metabolismo , Citosol/metabolismo , ADN Bacteriano , ADN de Plantas/aislamiento & purificación , Germinación/efectos de los fármacos , Germinación/genética , Mutagénesis Sitio-Dirigida , Óxido Nítrico/metabolismo , Oxilipinas/metabolismo , Vía de Pentosa Fosfato , Peroxisomas/metabolismo , Fosfogluconato Deshidrogenasa/química , Fosfogluconato Deshidrogenasa/genética , Hojas de la Planta/metabolismo , Plastidios , Polen/efectos de los fármacos , Polen/crecimiento & desarrollo , Prostaglandinas D/antagonistas & inhibidores , Semillas/efectos de los fármacos , Semillas/crecimiento & desarrollo , Análisis de Secuencia de ProteínaRESUMEN
BACKGROUND: There are concerns that diminished prostaglandin action in fetal life could increase the risk of congenital malformations. Many endocrine-disrupting chemicals have been found to suppress prostaglandin synthesis, but to our knowledge, pesticides have never been tested for these effects. OBJECTIVES: We assessed the ability of pesticides that are commonly used in the European Union to suppress prostaglandin D2 (PGD2) synthesis. METHODS: Changes in PGD2 secretion in juvenile mouse Sertoli cells (SC5 cells) were measured using an ELISA. Coincubation with arachidonic acid (AA) was conducted to determine the site of action in the PGD2 synthetic pathway. Molecular modeling studies were performed to assess whether pesticides identified as PGD2-active could serve as ligands of the cyclooxygenase-2 (COX-2) binding pocket. RESULTS: The pesticides boscalid, chlorpropham, cypermethrin, cyprodinil, fenhexamid, fludioxonil, imazalil (enilconazole), imidacloprid, iprodione, linuron, methiocarb, o-phenylphenol, pirimiphos-methyl, pyrimethanil, and tebuconazole suppressed PGD2 production. Strikingly, some of these substances-o-phenylphenol, cypermethrin, cyprodinil, linuron, and imazalil (enilconazole)-showed potencies (IC50) in the range between 175 and 1,500 nM, similar to those of analgesics intended to block COX enzymes. Supplementation with AA failed to reverse this effect, suggesting that the sites of action of these pesticides are COX enzymes. The molecular modeling studies revealed that the COX-2 binding pocket can accommodate most of the pesticides shown to suppress PGD2 synthesis. Some of these pesticides are also capable of antagonizing the androgen receptor. CONCLUSIONS: Chemicals with structural features more varied than previously thought can suppress PGD2 synthesis. Our findings signal a need for in vivo studies to establish the extent of endocrine-disrupting effects that might arise from simultaneous interference with PGD2 signaling and androgen action. CITATION: Kugathas S, Audouze K, Ermler S, Orton F, Rosivatz E, Scholze M, Kortenkamp A. 2016. Effects of common pesticides on prostaglandin D2 (PGD2) inhibition in SC5 mouse Sertoli cells, evidence of binding at the COX-2 active site, and implications for endocrine disruption. Environ Health Perspect 124:452-459; http://dx.doi.org/10.1289/ehp.1409544.
Asunto(s)
Ciclooxigenasa 2/metabolismo , Disruptores Endocrinos/toxicidad , Plaguicidas/toxicidad , Prostaglandina D2/antagonistas & inhibidores , Células de Sertoli/efectos de los fármacos , Antagonistas de Receptores Androgénicos , Animales , Ácido Araquidónico/metabolismo , Dominio Catalítico , Masculino , Ratones , Modelos Moleculares , Prostaglandina D2/metabolismo , Unión Proteica , Células de Sertoli/metabolismoRESUMEN
Androgenetic alopecia is the progressive miniaturization of the scalp's terminal follicles in aging men. Over 40% of Caucasian men develop hair loss by the age of 40. Despite its prevalence, there are only two FDA approved medications to treat the condition. Recognizing the unmet need, new medical, procedural, and surgical treatments are being adopted to combat progressive hair loss. This review examines emerging hair loss treatments including medical therapies that the target prostaglandins, low level light therapy, platelet rich plasma injections, and robotic hair transplantation.
Asunto(s)
Alopecia/terapia , Folículo Piloso/trasplante , Terapia por Luz de Baja Intensidad , Plasma Rico en Plaquetas , Alopecia/metabolismo , Dinoprost/análogos & derivados , Humanos , Masculino , Prostaglandina D2/antagonistas & inhibidores , Prostaglandinas/metabolismo , Procedimientos Quirúrgicos RobotizadosRESUMEN
The authors investigated the effect of manassantin B (Man B) isolated from Saururus chinensis (S. chinensis) on cyclooxygenase-2 (COX-2)-dependent prostaglandin D2 (PGD2) generation in mouse bone marrow derived-mast cells (BMMCs). Man B inhibited the generation of PGD2 dose-dependently by inhibiting COX-2 expression in immunoglobulin E (IgE)/Ag-stimulated BMMCs. To elucidate the mechanism responsible for the inhibition of COX-2 expression by Man B, the effects of Man B on the activation of nuclear factor-kappaB (NF-κB), a transcription factor essential and mitogen-activated protein kinases (MAPKs) for COX-2 induction, were examined. Man B attenuated the nuclear translocation of NF-κB p65 and its DNA-binding activity by inhibiting inhibitors of kappa Bα (IκBα) degradation and concomitantly suppressing IκB kinase (IKK) phosphorylation. In addition, Man B suppressed phosphorylation of MAPKs including extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun NH2-terminal kinase (JNK) and p38. It was also found that Man B suppressed Fyn kinase activation and consequent downstream signaling processes, including those involving Syk, Gab2, and Akt. Taken together, the present results suggest that Man B suppresses COX-2 dependent PGD2 generation by primarily inhibiting Fyn kinase in FcεRI-mediated mast cells.
Asunto(s)
Inhibidores de la Ciclooxigenasa 2/farmacología , Furanos/farmacología , Mastocitos/efectos de los fármacos , Prostaglandina D2/antagonistas & inhibidores , Animales , Células de la Médula Ósea/citología , Células Cultivadas , Ciclooxigenasa 2/metabolismo , Inhibidores de la Ciclooxigenasa 2/aislamiento & purificación , Furanos/aislamiento & purificación , Masculino , Mastocitos/metabolismo , Ratones , Ratones Endogámicos BALB C , Proteínas Quinasas Activadas por Mitógenos/metabolismo , FN-kappa B/metabolismo , Fitoterapia , Raíces de Plantas/química , Prostaglandina D2/metabolismo , Proteínas Proto-Oncogénicas c-fyn/metabolismo , SaururaceaeRESUMEN
The stem and root barks of Ulmus davidiana var. japonica (Ulmaceae) have been used to treat inflammatory diseases including mastitis, rhinitis, sinusitis, and enteritis. In an ongoing study focused on the discovery of natural anti-inflammatory compounds from natural products, a methanol extract of the stem and root barks of U. davidiana var. japonica showed anti-inflammatory activities. Activity-guided fractionation of the methanol extract yielded a new trihydroxy fatty acid, 9,12,13-trihydroxyoctadeca-10(Z),15(Z)-dienoic acid (1), and a known compound, pinellic acid (2). These two trihydroxy fatty acids 1 and 2 inhibited prostaglandin D2 production with IC50 values of 25.8 and 40.8 µM, respectively. These results suggest that 9,12,13-trihydroxyoctadeca-10(Z),15(Z)-dienoic acid (1) and pinellic acid (2) are among the anti-inflammatory principles in this medicinal plant.
Asunto(s)
Antiinflamatorios/farmacología , Ácidos Grasos/farmacología , Extractos Vegetales/farmacología , Prostaglandina D2/antagonistas & inhibidores , Ulmus/química , Animales , Línea Celular , Ácidos Grasos Insaturados/farmacología , Concentración 50 Inhibidora , Masculino , Ratones , Ácidos Oléicos/farmacología , Raíces de Plantas/química , Tallos de la Planta/química , Plantas Medicinales/químicaRESUMEN
Methyl gallate (MG) is a medicinal herbal product that is isolated from Paeonia lactiflora that inhibits cyclooxygenase-2 (COX-2) dependent phases of prostaglandin D2 (PGD2) generation in bone marrow-derived mast cells (BMMC) in a concentration-dependent manner with an IC50 values of 17.0 microM. This compound also found inhibited the COX-2-dependent conversion of the exogenous arachidonic acid to PGD2 in a dose-dependent manner with an IC50 values of 19.0 microM, using a COX enzyme assay kit. However, at concentrations up to 80 microM, MG did not inhibit COX-2 protein expression in BMMC, indicating that MG inhibits COX-2 activity directly. Furthermore, MG consistently inhibited the production of leukotriene C4 (LTC4) in a dose dependent manner, with an IC50 value of 5.3 microM. These results demonstrate that MG has a dual cyclooxygenase-2/5-lipoxygenase inhibitory activity, which might provide the basis for novel anti-inflammatory drugs.
Asunto(s)
Araquidonato 5-Lipooxigenasa/metabolismo , Ácido Araquidónico/metabolismo , Células de la Médula Ósea/efectos de los fármacos , Ciclooxigenasa 2/metabolismo , Ácido Gálico/análogos & derivados , Mastocitos/efectos de los fármacos , Animales , Células de la Médula Ósea/enzimología , Línea Celular Tumoral , Inhibidores de la Ciclooxigenasa/aislamiento & purificación , Inhibidores de la Ciclooxigenasa/farmacología , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/aislamiento & purificación , Inhibidores Enzimáticos/farmacología , Ácido Gálico/química , Ácido Gálico/aislamiento & purificación , Ácido Gálico/farmacología , Interleucina-10/farmacología , Leucotrieno C4/antagonistas & inhibidores , Leucotrieno C4/biosíntesis , Lipopolisacáridos/farmacología , Masculino , Mastocitos/enzimología , Ratones , Ratones Endogámicos BALB C , Estructura Molecular , Paeonia/química , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Hojas de la Planta/química , Tallos de la Planta/química , Prostaglandina D2/antagonistas & inhibidores , Prostaglandina D2/biosíntesis , Factor de Células Madre/farmacologíaRESUMEN
BACKGROUND: A dry powder inhaler of KP-496 is currently in clinical development in Japan as an anti-asthmatic agent. The aim of this study was to evaluate the in vitro pharmacological profile of KP-496. METHODS: The antagonistic activities of KP-496 for leukotriene (LT) D(4) and thromboxane (TX) A(2) receptors were examined using the LTD(4)- and U46619-induced contractions of the isolated guinea pig trachea. The selectivity of KP-496 was examined using various agonist-induced contractions in the isolated guinea pig trachea. RESULTS: KP-496 produced parallel rightward shifts of the LTD(4) and U46619 concentration-response curves in a concentration-dependent manner. Schild plot analyses of the antagonistic activities of KP-496 demonstrated that it is a competitive antagonist for LTD(4) and TXA(2) receptors with pA(2) values of 8.64 and 8.23, respectively. The LTD(4) antagonistic activity of KP-496 was comparable to that of pranlukast and zafirlukast but was more potent than that of montelukast. The TXA(2) antagonistic activity of KP-496 was comparable to that of seratrodast. KP-496 and seratrodast also inhibited the prostaglandin (PG) D(2)- and PGF(2alpha)-induced contractions of the isolated guinea pig trachea. KP-496 had no effect on the histamine-, acetylcholine-, serotonin- and substance P-induced contractions of the isolated guinea pig trachea. CONCLUSIONS: These results indicate that KP-496 is a selective dual antagonist for LTD(4) and TXA(2) receptors. LTD(4) and TXA(2) play important roles in asthma, and antagonists for these mediators are being used for the treatment of asthma. Thus, KP-496 is expected to become a novel potent therapeutic agent for asthma.
Asunto(s)
Antagonistas de Leucotrieno/farmacología , Leucotrieno D4/antagonistas & inhibidores , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Antagonistas de Prostaglandina/farmacología , Receptores de Tromboxano A2 y Prostaglandina H2/antagonistas & inhibidores , Tráquea/efectos de los fármacos , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/antagonistas & inhibidores , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacología , Acetatos/farmacología , Acetilcolina/farmacología , Albuterol/farmacología , Animales , Atropina/farmacología , Benzoquinonas/farmacología , Carbacol/farmacología , Cromonas/farmacología , Ciclopropanos , Dinoprost/antagonistas & inhibidores , Dinoprost/farmacología , Evaluación Preclínica de Medicamentos , Cobayas , Ácidos Heptanoicos/farmacología , Histamina/farmacología , Técnicas In Vitro , Indoles , Indometacina/farmacología , Ketanserina/farmacología , Cetotifen/farmacología , Leucotrieno D4/agonistas , Leucotrieno D4/farmacología , Masculino , Fenilcarbamatos , Polvos , Procaterol/farmacología , Prostaglandina D2/antagonistas & inhibidores , Prostaglandina D2/farmacología , Quinolinas/farmacología , Receptores de Tromboxano A2 y Prostaglandina H2/agonistas , Serotonina/farmacología , Sustancia P/farmacología , Sulfuros , Sulfonamidas , Compuestos de Tosilo/farmacología , Triptófano/análogos & derivados , Triptófano/farmacologíaRESUMEN
Ginkgetin, a biflavone from Ginkgo biloba leaves, was previously reported to be a phospholipase A(2) inhibitor and this compound showed the potent antiarthritic activity in rat adjuvant-induced arthritis as well as analgesic activity. This investigation was carried out to find effects on cyclooxygenase-2 (COX-2) in vitro effect. Ginkgetin inhibits COX-2 dependent phases of prostaglandin D(2) (PGD(2)) generation in bone marrow-derived mast cells (BMMC) in a concentration-dependent manner with IC(50) values of 0.75 microM. Western blotting probed with specific anti-COX-2 antibodies showed that the decrease in quantity of the PGD(2) product was accompanied by a decrease in the COX-2 protein level. In addition, this compound consistently inhibited the production of leukotriene C(4) (LTC(4)) in a dose dependent manner, with an IC(50) value of 0.33 microM. These results demonstrate that ginkgetin has a dual cyclooxygenase-2/5-lipoxygenase inhibitory activity. Furthermore, this compound also inhibited degranulation reaction in a dose dependent manner, with an IC(50) value of 6.52 microM. Therefore, this compound might provide a basis for novel anti-inflammatory agents.
Asunto(s)
Biflavonoides/farmacología , Células de la Médula Ósea/efectos de los fármacos , Inhibidores de la Ciclooxigenasa 2/farmacología , Flavonoides/farmacología , Ginkgo biloba , Inhibidores de la Lipooxigenasa , Mastocitos/efectos de los fármacos , Animales , Araquidonato 5-Lipooxigenasa/metabolismo , Biflavonoides/química , Biflavonoides/aislamiento & purificación , Células de la Médula Ósea/metabolismo , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Inhibidores de la Ciclooxigenasa 2/química , Relación Dosis-Respuesta a Droga , Flavonoides/química , Flavonoides/aislamiento & purificación , Interleucina-10/farmacología , Leucotrieno C4/antagonistas & inhibidores , Leucotrieno C4/genética , Leucotrieno C4/metabolismo , Lipopolisacáridos/farmacología , Masculino , Mastocitos/metabolismo , Mastocitos/patología , Proteínas de la Membrana/antagonistas & inhibidores , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos BALB C , Hojas de la Planta , Prostaglandina D2/antagonistas & inhibidores , Prostaglandina D2/metabolismo , Regulación hacia Arriba , beta-N-Acetilhexosaminidasas/antagonistas & inhibidores , beta-N-Acetilhexosaminidasas/metabolismoRESUMEN
1. The potent bronchoconstrictors prostaglandin (PG) D2, PG F2 alpha and thromboxane A2 are thought to have a role in the pathogenesis of asthma, mediated via the thromboxane (TP) receptor. 2. BAY u 3405 is a new potent selective competitive TP receptor antagonist. 3. The effect of single oral doses of 20 mg and 50 mg BAY u 3405 was examined against histamine and PG D2 bronchial provocation at 90 min after drug ingestion and, for the 20 mg dose alone, at 60 min after ingestion, in randomised, double-blind placebo controlled crossover studies. A time course study was performed with the 20 mg dose. 4. BAY u 3405 protected against PG D2 bronchial provocation. The 20 mg dose increased the amount of PG D2 required to produce a fall of 20% in the forced expiratory volume in 1 s by 6-fold and 16-fold at 60 min and 90 min after ingestion respectively, and the 50 mg dose by 14-fold at 90 min after ingestion. 5. The specificity of the drug was confirmed in vivo in that there was no significant protection against histamine bronchial provocation at either dose or at either time point. 6. The time course study showed significant protection against PG D2 bronchial provocation at 1 h and at 3 h after a single 20 mg oral dose. 7. There was no correlation between subjects in plasma BAY u 3405 concentration and drug effect. Within the subjects performing the time course study there was a strong correlation in time between drug effect and plasma BAY u 3405 concentration.(ABSTRACT TRUNCATED AT 250 WORDS)